The demonstration that CD4+ and CD8+ T cells have critical yet independent roles in controlling RSV infection in the absence of an antibody response suggests that vaccines that also elicit CD4+ and CD8+ T cell immunity may provide long-term protection against RSV infection and limit the severity of subsequent lung disease. This evidence concerns the gene CD4 and lung disorder.